British pharmaceutical giant AstraZeneca said on Tuesday that its goal is to reach 80 billion US dollars in sales by 2030, nearly double the 45.8 billion US dollars in 2023.
The company said it plans to launch 20 new drugs by 2030 to meet new gross revenue targets. Earlier, investment bank Jefferies (Jefferies) predicted that by 2031, AstraZeneca's annual sales would exceed 70 billion US dollars.
Astra set this goal ahead of its first Investor Day event in 10 years. The company's CEO, Suboco (Suboco), said he wants AstraZeneca to stand out in the competitive cancer drug market.